Literature DB >> 1604245

Western blot analysis of human IgG reactive with the collagenous portion of C1q: evidence of distinct binding specificities.

U Mårtensson1, A G Sjöholm, G Sturfelt, L Truedsson, A B Laurell.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) with purified collagenous C1q fragments in the solid phase was used for detection of C1q-specific immunoglobulins in the sera of twelve patients with systemic lupus erythematosus (SLE) or the SLE-like disease hypocomplementemic urticarial vasculitis syndrome (HUVS). By clinical criteria, four patients had SLE, and three HUVS. Five patients had overlap syndromes. All patients demonstrated high concentrations of C1q-specific IgG and markedly low concentrations of circulating C1q. Detection of C1q-specific IgG in SLE sera was facilitated by employment of saturating concentrations of collagenous C1q fragments in the solid-phase ELISA. When added to SLE serum, immune complex-fixed C1q inhibited binding of IgG to the C1q fragments, whereas addition of C1q alone had limited inhibitory effects. Under similar conditions, using approximately equimolar amounts of C1q relative to solid-phase C1q fragments, no ELISA inhibition was obtained after addition of C1q or immune complex-fixed C1q to a HUVS serum. Even in large excess, purified C1q did not inhibit binding of HUVS-IgG to solid-phase C1q fragments. Thus, possible interactions between HUVS-IgG and native Clq are probably of low affinity. By Western blot analysis, IgG reactive with the B and C chains of C1q was found in the eight patients with evidence of HUVS, five of whom also showed IgG binding to C'-C' and A'-B' dimers of collagenous C1q fragments. Sera from SLE patients were negative by Western blot analysis. It seems likely that C1q-specific IgG in SLE primarily recognizes assembled C1q molecules or collagenous C1q fragments expressing conformational epitopes of bound C1q. Interestingly, patients with evidence of HUVS fairly consistently had zymogen (C1r-C1s)2 complexes in their serum, while patients with SLE showed high concentrations of complexes containing Cl inhibitor, C1r and C1s. Different binding specificities of C1q-reactive IgG could be of importance with regard to pathogenetic mechanisms in SLE and HUVS. There was no correlation between findings of C1q-specific IgG and a variety of autoantibodies associated with SLE and SLE-like disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1604245     DOI: 10.1111/j.1365-3083.1992.tb02982.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  10 in total

Review 1.  Complement in the immunopathogenesis of rheumatic disease.

Authors:  Gunnar Sturfelt; Lennart Truedsson
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

Review 2.  Antibodies against C1q in patients with systemic lupus erythematosus.

Authors:  Marten Trendelenburg
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

3.  Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review.

Authors:  Andrew Buck; Jim Christensen; Morgan McCarty
Journal:  J Clin Aesthet Dermatol       Date:  2012-01

Review 4.  Urticarial vasculitis.

Authors:  Joe Venzor; Wai L Lee; David P Huston
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

5.  Autoantibodies against complement receptor 1 (CD35) in SLE, liver cirrhosis and HIV-infected patients.

Authors:  S Sadallah; C Hess; M Trendelenburg; C Vedeler; M Lopez-Trascasa; J A Schifferli
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

Review 6.  Interpretation of Serological Complement Biomarkers in Disease.

Authors:  Kristina N Ekdahl; Barbro Persson; Camilla Mohlin; Kerstin Sandholm; Lillemor Skattum; Bo Nilsson
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

Review 7.  Autoantibodies against complement component C1q in systemic lupus erythematosus.

Authors:  Marten Trendelenburg
Journal:  Clin Transl Immunology       Date:  2021-04-29

8.  Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus.

Authors:  Jessica S Kleer; Pascal A Rabatscher; Jessica Weiss; Joel Leonardi; Severin B Vogt; Andrea Kieninger-Gräfitsch; Carlo Chizzolini; Uyen Huynh-Do; Camillo Ribi; Marten Trendelenburg
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

9.  Anti-C1q antibodies in systemic lupus erythematosus.

Authors:  A-M Orbai; L Truedsson; G Sturfelt; O Nived; H Fang; G S Alarcón; C Gordon; Jt Merrill; P R Fortin; I N Bruce; D A Isenberg; D J Wallace; R Ramsey-Goldman; S-C Bae; J G Hanly; J Sanchez-Guerrero; A E Clarke; C B Aranow; S Manzi; M B Urowitz; D D Gladman; K C Kalunian; M I Costner; V P Werth; A Zoma; S Bernatsky; G Ruiz-Irastorza; M A Khamashta; S Jacobsen; J P Buyon; P Maddison; M A Dooley; R F Van Vollenhoven; E Ginzler; T Stoll; C Peschken; J L Jorizzo; J P Callen; S S Lim; B J Fessler; M Inanc; D L Kamen; A Rahman; K Steinsson; A G Franks; L Sigler; S Hameed; N Pham; R Brey; M H Weisman; G McGwin; L S Magder; M Petri
Journal:  Lupus       Date:  2014-08-14       Impact factor: 2.911

Review 10.  Hypocomplementemic urticarial vasculitis syndrome.

Authors:  Luis J Jara; Carmen Navarro; Gabriela Medina; Olga Vera-Lastra; Miguel A Saavedra
Journal:  Curr Rheumatol Rep       Date:  2009-12       Impact factor: 4.686

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.